# Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)

> **NCT01397916** · — · COMPLETED · sponsor: **Tampere University Hospital** · enrollment: 73 (actual)

## Conditions studied

- CLL

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01397916
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397916, "Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01397916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*